Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Net Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Net Margin for 15 consecutive years, with 12.21% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 1244.0% to 12.21% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 13.43% through Dec 2025, up 485.0% year-over-year, with the annual reading at 13.43% for FY2025, 485.0% up from the prior year.
  • Net Margin for Q4 2025 was 12.21% at Niagen Bioscience, down from 13.47% in the prior quarter.
  • The five-year high for Net Margin was 24.65% in Q4 2024, with the low at 51.17% in Q3 2021.
  • Average Net Margin over 5 years is 10.56%, with a median of 5.9% recorded in 2022.
  • The sharpest move saw Net Margin crashed -2144bps in 2021, then skyrocketed 3612bps in 2023.
  • Over 5 years, Net Margin stood at 29.98% in 2021, then soared by 77bps to 6.88% in 2022, then soared by 108bps to 0.54% in 2023, then skyrocketed by 4483bps to 24.65% in 2024, then plummeted by -50bps to 12.21% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 12.21%, 13.47%, and 11.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.